Chimerix Inc/ US16934W1062 /
2024-03-18 9:00:00 PM | Chg. -0.0500 | Volume | Bid9:00:00 AM | Ask9:00:00 AM | High | Low |
---|---|---|---|---|---|---|
1.1000USD | -4.35% | 224,464 Turnover: 240,482.6137 |
1.0700Bid Size: 100 | 1.2900Ask Size: 100 | 1.1700 | 1.1000 |
GlobeNewswire
02-29
Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update
GlobeNewswire
02-22
Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Upd...
GlobeNewswire
2023-11-16
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating an...
GlobeNewswire
2023-11-02
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
GlobeNewswire
2023-10-26
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on Novembe...
GlobeNewswire
2023-08-16
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC20...
GlobeNewswire
2022-03-01
Chimerix Reports Fourth Quarter and Year End 2021 Financial Results and Provides Operational Update
GlobeNewswire
2022-02-28
Chimerix to Present at Cowen and Company 42nd Annual Health Care Conference
GlobeNewswire
2022-02-24
Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) ...
GlobeNewswire
2022-02-22
Chimerix to Report Fourth Quarter and Year End 2021 Financial Results and Provide an Operational Upd...
GlobeNewswire
2021-11-19
Chimerix Announces Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma to Be Pre...
GlobeNewswire
2021-11-11
Chimerix Announces Upcoming Presentations at the Society for Neuro-Oncology Annual Meeting 2021
GlobeNewswire
2021-11-04
Chimerix Reports Third Quarter 2021 Financial Results and Provides Operational Update
GlobeNewswire
2021-11-04
Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma